

Heinz-Josef Lenz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8224219/publications.pdf>

Version: 2024-02-01

235
papers

24,254
citations

18887

64
h-index

9118

149
g-index

236
all docs

236
docs citations

236
times ranked

28266
citing authors

#	ARTICLE	IF	CITATIONS
1	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
2	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	0.8	283
3	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. <i>Cell Chemical Biology</i> , 2022, 29, 555-571.e11.	2.5	12
4	Association of Homologous Recombinationâ€“DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 227-236.	1.9	4
5	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2022, 41, 260-267.	2.6	7
6	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancerâ€“â‰¥ 70 years. <i>European Journal of Cancer</i> , 2022, 163, 1-15.	1.3	6
7	Comprehensive Analysis of R-Spondin Fusions and <i>RNF43</i> Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1863-1870.	3.2	16
8	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	3.2	11
9	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. <i>Clinical Cancer Research</i> , 2022, 28, 1690-1700.	3.2	7
10	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. <i>Oncogene</i> , 2022, 41, 3455-3460.	2.6	19
11	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
12	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2022, 172, 22-30.	1.3	3
13	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	1.4	6
14	Clinical Validation of a Machine-learningâ€“derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	3.2	28
15	Humanâ€“specific polymorphic pseudogenization of <i>SIGLEC12</i> protects against advanced cancer progression. <i>FASEB BioAdvances</i> , 2021, 3, 69-82.	1.3	14
16	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. <i>Clinical Colorectal Cancer</i> , 2021, 20, 84-95.e8.	1.0	15
17	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275.	3.2	13
18	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2723-2733.	3.2	33

#	ARTICLE	IF	CITATIONS
19	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021, 21, 285-295.	0.9	3
20	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1153-1160.	1.9	1
21	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
22	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
23	Clocking cancer: the circadian clock as a target in cancer therapy. <i>Oncogene</i> , 2021, 40, 3187-3200.	2.6	41
24	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021, 1, 311-325.	0.1	0
25	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, 12191.	1.6	3
26	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 150, 133-142.	1.3	1
27	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
28	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021, 40, 4894-4905.	2.6	19
29	Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS/MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. <i>Annals of Oncology</i> , 2021, 32, 906-916.	0.6	15
30	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 317-324.	1.0	4
31	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	2.3	9
32	Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, , .	2.9	1
33	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 10-16.	0.7	2
34	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	1.4	22
35	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	1.4	8
36	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0239439.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
38	Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. <i>Oncologist</i> , 2020, 25, e1879-e1885.	1.9	2
39	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
40	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020, 6, .	4.7	18
41	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	3.2	55
42	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
43	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
44	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	1.6	5
45	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. <i>British Journal of Cancer</i> , 2020, 122, 1518-1524.	2.9	31
46	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
47	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020, 12, 1742.	1.7	4
48	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , 2020, 111, 441-450.	1.7	8
49	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020, 131, 89-97.	1.3	9
50	Title is missing!. , 2020, 15, e0239439.		0
51	Title is missing!. , 2020, 15, e0239439.		0
52	Title is missing!. , 2020, 15, e0239439.		0
53	Title is missing!. , 2020, 15, e0239439.		0
54	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 146-157.	3.0	129

#	ARTICLE	IF	CITATIONS
55	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
56	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019, 45, 139-154.	2.7	36
57	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1070-1082.	5.1	169
58	What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 754-756.	3.0	0
59	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101912.	3.4	109
60	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. <i>Clinical Colorectal Cancer</i> , 2019, 18, 269-279.e5.	1.0	4
61	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	3.2	65
62	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	9.4	315
63	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
64	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). <i>Journal of Clinical Oncology</i> , 2019, 37, 1876-1885.	0.8	169
65	The safety and efficacy of trifluridine-tyipiracil for metastatic colorectal cancer: A pharmacy perspective. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 339-348.	0.5	7
66	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019, 111, 138-147.	1.3	4
67	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 2450-2458.	2.3	5
68	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. <i>Journal of Clinical Oncology</i> , 2019, 37, 1217-1227.	0.8	234
69	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2988-2995.	3.2	42
70	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019, 107, 100-114.	1.3	12
71	Genetic variants in CCL5 and CCR5 genes and serum VEGF levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2019, 144, 2567-2577.	2.3	8
72	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019, 42, 211-233.	1.4	76

#	ARTICLE	IF	CITATIONS
73	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2019, 37, 635-635.	0.8	31
74	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
75	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488.	1.0	12
76	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 15-22.	3.4	149
77	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
78	The subgroups of the phase III RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018, 90, 63-72.	1.3	69
79	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€œFoot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e395-e414.	1.0	25
80	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.	2.9	29
81	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018, 45, 124-132.	0.8	9
82	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation â€œ A target for novel cancer therapy. <i>Cancer Treatment Reviews</i> , 2018, 63, 40-47.	3.4	867
83	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018, 24, 784-793.	3.2	23
84	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repairâ€œDeficient/Microsatellite Instabilityâ€œHigh Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	0.8	1,525
85	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 69.	1.3	25
86	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1451-1455.	2.9	19
87	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018, 18, 623-632.	0.9	8
88	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , 2018, 18, 99.	1.8	48
89	Differentiation Therapy Targeting the β -Catenin/CBP Interaction in Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 95.	1.7	39
90	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1319-1327.	1.9	131

#	ARTICLE	IF	CITATIONS
91	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	1.1	5
92	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. Clinical Colorectal Cancer, 2018, 17, 215-222.e3.	1.0	4
93	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2018, 36, 3576-3576.	0.8	2
94	Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 692-692.	0.8	1
95	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. Journal of Cancer Metastasis and Treatment, 2018, 4, 12.	0.5	5
96	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clinical Advances in Hematology and Oncology, 2018, 16, 735-745.	0.3	59
97	What We Know About Stage II and III Colon Cancer: Itâ€™s Still Not Enough. Targeted Oncology, 2017, 12, 265-275.	1.7	25
98	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	3.8	670
99	Predictive value of <i>TLR7</i> polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. International Journal of Cancer, 2017, 141, 1222-1230.	2.3	21
100	Single nucleotide polymorphisms in the IGF1R pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. International Journal of Cancer, 2017, 141, 383-392.	2.3	10
101	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer, 2017, 77, 13-20.	1.3	19
102	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. European Journal of Cancer, 2017, 86, 197-206.	1.3	22
103	Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1161-1169.	1.1	5
104	Colorectal cancer: epigenetic alterations and their clinical implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 439-448.	3.3	48
105	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2017, 18, 1182-1191.	5.1	2,058
106	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
107	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. European Journal of Cancer, 2017, 84, 69-80.	1.3	212
108	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology, 2017, 28, 2780-2785.	0.6	28

#	ARTICLE	IF	CITATIONS
109	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 580-590.	0.3	2
110	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 194.	3.4	555
111	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. <i>Oncotarget</i> , 2017, 8, 86356-86368.	0.8	147
112	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3531-3531.	0.8	26
113	Randomized trial of irinotecan and cetuximab with or without vemurafenib in <i>BRAF</i> -mutant metastatic colorectal cancer (SWOG 1406).. <i>Journal of Clinical Oncology</i> , 2017, 35, 520-520.	0.8	100
114	Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3585-3585.	0.8	1
115	The safety of monoclonal antibodies for treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 799-808.	1.0	24
116	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1091-1108.	1.3	9
117	Phase II Study of Olaparib (AZD2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 172-177.	1.9	58
118	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2814-2821.	1.9	9
119	A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2251-2258.	1.9	6
120	Molecular Pathways: Cachexia Signaling—A Targeted Approach to Cancer Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 3999-4004.	3.2	85
121	Clinical Significance of <i>TLR1</i> I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1740-1745.	1.9	9
122	A novel antimetabolite: TAS-102 for metastatic colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 355-365.	1.3	11
123	<i> Twist1</i> Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1405-1411.	1.9	11
124	Overcoming resistance to anti-EGFR therapy—where do we stand?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 258-259.	8.2	10
125	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 117-126.	2.0	1
126	Prognostic Impact of <i>IL6</i> Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3218-3226.	3.2	21

#	ARTICLE	IF	CITATIONS
127	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	0.8	116
128	Impact of primary (1 st) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3504-3504.	0.8	249
129	Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3590-3590.	0.8	1
130	MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 493-493.	0.8	15
131	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , 2016, 7, 53668-53678.	0.8	26
132	CDX2 as a Prognostic Biomarker in Colon Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 2183.	13.9	5
133	TAS-102, a novel antitumor agent: A review of the mechanism of action. <i>Cancer Treatment Reviews</i> , 2015, 41, 777-783.	3.4	115
134	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015, 121, 1898-1905.	2.0	12
135	Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. <i>Annals of Oncology</i> , 2015, 26, 332-339.	0.6	28
136	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	385
137	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 692-700.	0.8	686
138	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. <i>Clinical Cancer Research</i> , 2015, 21, 1583-1590.	3.2	8
139	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2401-2408.	1.9	25
140	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	5.1	286
141	The Molecular Taxonomy of Colorectal Cancer: What's New?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 118-124.	1.0	2
142	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	13.9	1,027
143	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. <i>Annals of Oncology</i> , 2015, 26, 1728-1733.	0.6	8
144	Molecular Classification of Gastric Adenocarcinoma: Translating New Insights from The Cancer Genome Atlas Research Network. <i>Current Treatment Options in Oncology</i> , 2015, 16, 17.	1.3	53

#	ARTICLE	IF	CITATIONS
145	Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 30-37.	0.7	12
146	Pharmacogenomics of fluorouracil-based chemotherapy toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 811-821.	1.5	43
147	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2374-2381.	1.9	4
148	Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. <i>Clinical Cancer Research</i> , 2015, 21, 5002-5007.	3.2	61
149	Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 43-60.	0.9	24
150	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3558-3558.	0.8	15
151	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3625-TPS3625.	0.8	1
152	Panitumumab: leading to better overall survival in metastatic colorectal cancer?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 535-548.	1.4	1
153	Panitumumab safety for treating colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1-9.	1.0	9
154	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin $\beta 1$. <i>Science Signaling</i> , 2014, 7, ra58.	1.6	32
155	Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 528-539.	1.9	37
156	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. <i>Cell Reports</i> , 2014, 7, 1940-1955.	2.9	90
157	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 282-298.	12.5	312
158	Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment Approach. <i>Clinical Cancer Research</i> , 2014, 20, 3064-3070.	3.2	13
159	The potential of targeting Wnt/ β 2-catenin in colon cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 611-615.	1.5	198
160	So Much Effort, So Little Progress?. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	5
161	Polymorphisms in folateâ€œmetabolizing enzymes and response to 5â€œfluorouracil among patients with stage II or III rectal cancer (INTâ€œ0144; SWOG 9304). <i>Cancer</i> , 2014, 120, 3329-3337.	2.0	15
162	CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. <i>International Journal of Cancer</i> , 2014, 135, 232-237.	2.3	13

#	ARTICLE	IF	CITATIONS
163	Sustained inhibition of deacetylases is required for the antitumor activity of the histone deacetylase inhibitors panobinostat and vorinostat in models of colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 845-857.	1.2	18
164	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 303-312.	6.3	2,276
165	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2203-2220.	0.9	4
166	Markers of Response for the Antiangiogenic Agent Bevacizumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 1219-1230.	0.8	309
167	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2261-2272.	1.9	19
168	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. <i>PLoS ONE</i> , 2013, 8, e66774.	1.1	64
169	A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2501-2501.	0.8	75
170	Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3514-3514.	0.8	5
171	Influence of Sex on the Survival of Patients With Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2265-2272.	0.8	112
172	Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase-Targeted Therapies in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 616-628.	1.9	44
173	A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 1726-1734.	3.2	186
174	Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 528-535.	1.4	2
175	Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). <i>Gastroenterology Clinics of North America</i> , 2012, 41, 189-209.	1.0	31
176	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 263-271.	1.0	1
177	Targeting IL-8 in colorectal cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 491-497.	1.5	72
178	The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1353-1364.	1.9	97
179	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 537-544.	1.1	35
180	LMTK3 polymorphism in patients with metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 471-471.	0.8	6

#	ARTICLE	IF	CITATIONS
181	Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5783-5792.	3.2	79
182	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. <i>Nature Medicine</i> , 2011, 17, 715-719.	15.2	118
183	Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity <i>in vitro</i> and <i>in vivo</i> in colon cancer cell line models. <i>International Journal of Cancer</i> , 2011, 128, 2038-2049.	2.3	379
184	Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. <i>International Journal of Cancer</i> , 2011, 129, 1096-1104.	2.3	28
185	Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. <i>Pharmacogenomics</i> , 2011, 12, 27-39.	0.6	20
186	The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models. <i>Cancer Research</i> , 2011, 71, 3635-3648.	0.4	78
187	GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. <i>Annals of Oncology</i> , 2011, 22, 2431-2439.	0.6	25
188	Common Cancer Stem Cell Gene Variants Predict Colon Cancer Recurrence. <i>Clinical Cancer Research</i> , 2011, 17, 6934-6943.	3.2	91
189	A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. <i>Annals of Oncology</i> , 2011, 22, 104-109.	0.6	114
190	Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. <i>Journal of Gastrointestinal Oncology</i> , 2011, 2, 77-84.	0.6	151
191	A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 979-988.	1.1	52
192	Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 183-192.	1.0	0
193	The Colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information. <i>BMC Cancer</i> , 2010, 10, 687.	1.1	7
194	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients. <i>Clinical Cancer Research</i> , 2010, 16, 5591-5602.	3.2	43
195	Gender Disparities in Metastatic Colorectal Cancer Survival. <i>Clinical Cancer Research</i> , 2009, 15, 6391-6397.	3.2	168
196	Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. <i>International Journal of Cancer</i> , 2009, 125, 463-473.	2.3	68
197	DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. <i>BMC Medical Genomics</i> , 2009, 2, 67.	0.7	85
198	Pharmacogenomics and -genetics in colorectal cancer. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 375-380.	6.6	17

#	ARTICLE	IF	CITATIONS
199	Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology, 2008, 3, 87-99.	1.7	1
200	Individualization of therapy based on clinical and molecular parameters. Current Colorectal Cancer Reports, 2008, 4, 193-200.	1.0	3
201	First-line combination treatment of colorectal cancer with hepatic metastases: Choosing a targeted agent. Cancer Treatment Reviews, 2008, 34, S3-S7.	3.4	77
202	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2311-2319.	0.8	884
203	Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab. Clinical Cancer Research, 2008, 14, 7554-7563.	3.2	179
204	Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models. Clinical Cancer Research, 2008, 14, 6647-6655.	3.2	18
205	Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenetics and Genomics, 2008, 18, 161-168.	0.7	48
206	Management and Preparedness for Infusion and Hypersensitivity Reactions. Oncologist, 2007, 12, 601-609.	1.9	396
207	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. Oncologist, 2007, 12, 38-50.	1.9	218
208	Association of Methylenetetrahydrofolate Reductase Gene Polymorphisms and Sex-Specific Survival in Patients With Metastatic Colon Cancer. Journal of Clinical Oncology, 2007, 25, 3726-3731.	0.8	60
209	FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab. Journal of Clinical Oncology, 2007, 25, 3712-3718.	0.8	466
210	EGFR, HER2 and VEGF Pathways. Drugs, 2007, 67, 2045-2075.	4.9	125
211	Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumorVEGFAandVEGFRexpression in metastatic CRC patients. Pharmacogenomics, 2007, 8, 1705-1713.	0.6	66
212	Predictive and prognostic markers in colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 237-46.	0.8	9
213	Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Annals of Medicine, 2006, 38, 545-551.	1.5	49
214	Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics, 2006, 7, 67-88.	0.6	60
215	Determinants of chemosensitivity in gastric cancer. Current Opinion in Pharmacology, 2006, 6, 337-344.	1.7	41
216	Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenetics and Genomics, 2006, 16, 555-563.	0.7	21

#	ARTICLE	IF	CITATIONS
217	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 475-483.	0.7	97
218	Molecular determinants of irinotecan efficacy. <i>International Journal of Cancer</i> , 2006, 119, 2435-2442.	2.3	55
219	Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2006, 24, 4914-4921.	0.8	504
220	Pharmacogenomics and Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2006, 587, 211-231.	0.8	26
221	Molecular Determinants of Cetuximab Efficacy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3536-3544.	0.8	229
222	Gene Polymorphisms of Epidermal Growth Factor Receptor and its Downstream Effector, Interleukin-8, Predict Oxaliplatin Efficacy in Patients with Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 124-131.	1.0	64
223	Epidermal Growth Factor Receptor as a Target for Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2005, 5, S19-S27.	1.0	59
224	Antiangiogenic agents in cancer therapy. <i>Oncology</i> , 2005, 19, 17-25.	0.4	12
225	Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 947-955.	1.1	4
226	Integration of novel agents in the treatment of colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54 Suppl 1, S32-9.	1.1	29
227	The role of proteasome inhibitors in solid tumors. <i>Annals of Medicine</i> , 2004, 36, 296-303.	1.5	30
228	Pharmakogenetik in kolorektalen Karzinomen. <i>Onkologie</i> , 2003, 9, 860-864.	0.7	0
229	Tailoring chemotherapy in advanced colorectal cancer. <i>Current Opinion in Pharmacology</i> , 2003, 3, 378-385.	1.7	26
230	Implications of Genetic Testing in the Management of Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 73-88.	3.3	13
231	Pharmacogenetic aspects in treatment of colorectal cancer – an update. <i>Pharmacogenomics</i> , 2003, 4, 767-777.	0.6	5
232	A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. <i>Cancer Research</i> , 2003, 63, 2898-904.	0.4	279
233	Association Between Glutathione S-Transferase P1, T1, and M1 Genetic Polymorphism and Survival of Patients With Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 936-942.	3.0	350
234	Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2002, 17, 46-49.	1.0	94

#	ARTICLE	IF	CITATIONS
235	<i>ERCC1</i> and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 4298-4304.	0.8	601